Engene Therapeutics Inc. · NASDAQ:ENGN
Engene Therapeutics — Corporate Update (May 2026)
20 slides from Engene Therapeutics's corporate update, May 7, 2026
Slide 1: LEGEND Interim Data Update
LEGEND Interim Data Update May 7, 2026 Exhibit 99.2
Slide 2: Disclaimers: Cautionary Statement Regarding Forward-Looking Statements
Disclaimers Cautionary Statement Regarding Forward-Looking Statements This Presentation contains certain forward-looking statements within the meaning of the federal securities laws and "forward-looking information" within the meaning of Canadian securities laws (collectively, "forward-looking state
Slide 3: Introductory Remarks
Introductory Remarks
Slide 4: LEGEND Phase Cohort 1: CONSORT Diagram
LEGEND Phase 2 Cohort 1: CONSORT Diagram Enrolled 3-month 6-month 9-month 12-month Maintenance 125 Patients 1 Discontinued 1 no disease evaluation (censored*) 124 Completed Evaluation 103 Completed Evaluation 2 pending evaluation at 6-mos 19 Discontinued 18 non-CR 1 CR (censored*) 44 Completed Evalu
Slide 5: LEGEND Phase Cohort 1: Baseline Demographics and Disease Characteristics
LEGEND Phase 2 Cohort 1: Baseline Demographics and Disease Characteristics Characteristics Pivotal Cohort 1 (N=125) Age, years Median (Range) 71.0 (35.0-90.0) Sex, n (%) Female 24 (19.2%) Male 101 (80.8%) Race n (%) White 114 (91.2%) Asian 4 (3.2%) Black or African American 2 (1.6%) Not Reported 5 (
Slide 6: Detalimogene Demonstrated Favorable Safety and Tolerability Profile
Detalimogene Demonstrated Favorable Safety and Tolerability Profile TRAEs were Generally Mild and Reversible, Consistent with Catheterization TRAE= treatment-related adverse event. *One patient had a treatment-related pyelonephritis/sepsis that led to a dose interruption. No grade ≥ 3 TRAEs led to d
Slide 7: LEGEND Cohort Interim Efficacy Data
LEGEND Cohort 1 Interim Efficacy Data * Patients who discontinued without any disease evaluation or who discontinued after a CR are excluded from subsequent landmark response analysis. **Results do not include one patient with potential CR at 9 months that is currently considered a non-CR in the dat
Slide 8: Patients Post October 2025 Analysis Underperformed Earlier Subgroups
Patients Post October 2025 Analysis Underperformed Earlier Subgroups *Data disclosed in press release dated November 11, 2025, and reflect a data analysis of October 24, 2025. ** Includes i) patients whose first post-baseline assessment took place following October 24, 2025, and ii) one patient that
Slide 9: Bladder Rinse Opportunity
Bladder Rinse Opportunity
Slide 10: Surfactant Bladder Rinse Could Increase Transgene Expression
Surfactant Bladder Rinse Could Increase Transgene Expression Bladder lumen contains protective mucosal boundary layer DDX designed to spontaneously penetrate mucosal layer and transfect urothelium Surfactant bladder rinse designed to disrupt bladder mucosal barrier and further increase DDX permeabil
Slide 11: Detalimogene and Surfactant Bladder Rinse (Polidocanol) Designed to Improve Gene Expression
Detalimogene and Surfactant Bladder Rinse (Polidocanol) Designed to Improve Gene Expression, Shorten Dwell Time, and Improve Efficacy Increases Magnitude & Duration of Gene Expression Shortens Bladder Dwell Time Improves Efficacy % Survived at Study End pg IL-12/mg tissue protein pg IL-12/mg protein
Slide 12: Detalimogene and Surfactant Bladder Rinse LEGEND Cohort Underway
Detalimogene and Surfactant Bladder Rinse LEGEND Cohort Underway 20 trial sites activated in US and Canada and actively recruiting patients Simple 5-min pre-treatment of the bladder with 50 mL of 0.25% polidocanol solution prior to detalimogene administration Total detalimogene dwell time shortened
Slide 13: Market Research Insights
Market Research Insights
Slide 14: Community Urologists: Higher Volume with Fewer Resources and Staff
Community Urologists: Higher Volume with Fewer Resources and Staff Source: enGene sourced market research (survey n=100 urologists and uro-oncologists). Small Private Practice Large Urology Group Health System / Hospital Academic Medical Center Patients per Procedure Room Patients per Urologist
Slide 15: Less Than Half of Urologists Prescribe Branded Therapies to BCG-UR Patients
Less Than Half of Urologists Prescribe Branded Therapies to BCG-UR Patients Small Private Practice Large Urology Group Practice Hospital / Health System Academic Medical Center “I prescribe [Product X] and [Product Y]. I just cannot administer them in my office. I have to go to a hospital I have a c
Slide 16: Low Adoption of Branded Therapies Driven by Logistics and Cost to Acquire
Low Adoption of Branded Therapies Driven by Logistics and Cost to Acquire Reasons for Limited Use of Branded Therapies Rank Top 3 Source: Market Research (survey n=100 urologists and uro-oncologists).
Slide 17: Market Research Findings: Opportunities for Detalimogene
Market Research Findings: Opportunities for Detalimogene Challenge Detalimogene Opportunity Limited Resources Accessible in lower-resource settings: Nurse-administered without specialized procedure-room or BSL-2 hood requirements Burdensome Logistics Minimal logistical burden: No vial thaw, bench-to
Slide 18: Preliminary Efficacy and Durability Estimates
Preliminary Efficacy and Durability Estimates Data as of 21 April 2026; CI: 95% Confidence Interval. Data collection and cleaning is ongoing. These data are presented for informational purposes and are not based on any head-to-head or comparator clinical studies. Cross-trial comparisons are inherent
Slide 19: Closing Remarks and Q&A
Closing Remarks and Q&A
Slide 20: enGene
enGene | Non-Viral Genetic Medicine